A Phase II single-arm study to investigate tepotinib combined with cetuximab in RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) patients having acquired resistance to anti-EGFR antibody targeting therapy due to MET amplification (PERSPECTIVE)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 15 Sep 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Tepotinib (Primary)
Indications Colorectal cancer
Focus Adverse reactions; Therapeutic Use
Acronyms PERSPECTIVE
Sponsors EMD Serono Research & Development Institute; Merck KGaA

Most Recent Events

11 Jun 2022 This trial has been completed in France according to European Clinical Trials Database record.
11 May 2022 Status changed from active, no longer recruiting to discontinued.
04 Dec 2021 This trial has been discontinued in Italy according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight